Arhalofenic Acid

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H10ClF3O3
Molecular Weight	330.686
Optical Activity	( - )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)[C@H](OC1=CC(=CC=C1)C(F)(F)F)C2=CC=C(Cl)C=C2

InChI

InChIKey=DDTQLPXXNHLBAB-CYBMUJFWSA-N

InChI=1S/C15H10ClF3O3/c16-11-6-4-9(5-7-11)13(14(20)21)22-12-3-1-2-10(8-12)15(17,18)19/h1-8,13H,(H,20,21)/t13-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C15H10ClF3O3
Molecular Weight	330.686
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://ard.bmj.com/content/71/Suppl_3/450.3 | https://www.ncbi.nlm.nih.gov/pubmed/19404482

Arhalofenate is a uricosuric drug which lowers serum urate by blocking its reabsorption by the proximal tubules of the kidney. Arhalofenate activity is mediated by inhibition of URAT1, OAT4 and OAT10. Additionally, arhalofenate has been suggested to exert potent anti-inflammatory activity. Arhalofenate has completed Phase 2 and is ready to advance to Phase 3 as a novel potential treatment for gout. The drug was also tested in patients with type 2 diabetes mellitus (phase III study), where it demonstrated its ability to lower glucose level, acting as a selective, partial PPAR-gamma agonist. However, the development of arhalofenate as an anti-diabetic drug was terminated.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Solute carrier family 22 member 12 10 Target ID: Q96S37\|\|\|Q96DT2 Gene ID: 116085.0 Gene Symbol: SLC22A12 Target Organism: Homo sapiens (Human) Sources: http://ard.bmj.com/content/71/Suppl_3/450.3	Inhibitor 8297	92.0 µM [IC50]
Solute carrier family 22 member 11 12 Target ID: Q9NSA0 Gene ID: 55867.0 Gene Symbol: SLC22A11 Target Organism: Homo sapiens (Human) Sources: http://ard.bmj.com/content/71/Suppl_3/450.3	Inhibitor 8297	2.6 µM [IC50]
Solute carrier family 22 member 13 2 Target ID: Q9Y226 Gene ID: 9390.0 Gene Symbol: SLC22A13 Target Organism: Homo sapiens (Human) Sources: http://ard.bmj.com/content/71/Suppl_3/450.3	Inhibitor 8297	53.0 µM [IC50]
Peroxisome proliferator-activated receptor gamma 111 Target ID: P37231\|\|\|Q15179 Gene ID: 5468.0 Gene Symbol: PPARG Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/19404482	Partial Agonist 290	12.0 µM [EC50]
Peroxisome proliferator-activated receptor gamma 111 Target ID: CHEMBL235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19404482\|https://www.ncbi.nlm.nih.gov/pubmed/19389808\|https://www.ncbi.nlm.nih.gov/pubmed/18815616	Partial Agonist 290

Conditions

Condition	Modality	Targets	Highest Phase	Product
Gout 28 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26989892	Primary		Phase II 1132	Unknown Approved Use Unknown
Type 2 diabetes mellitus 259 Sources: https://www.clinicaltrials.gov/ct2/show/NCT00353587	Primary		Phase III 656	Unknown Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
140 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27980008	800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ARHALOFENATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2960 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27980008	800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ARHALOFENATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
50 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27980008	800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered:		ARHALOFENATE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26989892 Page: p.2030	unhealthy, ADULT n = 51 Health Status: unhealthy Condition: gout Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 51 Sources: https://pubmed.ncbi.nlm.nih.gov/26989892 Page: p.2030	Disc. AE: Abdominal pain, Headache... AEs leading to discontinuation/dose reduction: Abdominal pain (2%) Headache (2%) Skin rash (2%) Sources: https://pubmed.ncbi.nlm.nih.gov/26989892 Page: p.2030

AEs

AE	Significance	Dose	Population
Abdominal pain	2% Disc. AE	800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26989892 Page: p.2030	unhealthy, ADULT n = 51 Health Status: unhealthy Condition: gout Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 51 Sources: https://pubmed.ncbi.nlm.nih.gov/26989892 Page: p.2030
Headache	2% Disc. AE	800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26989892 Page: p.2030	unhealthy, ADULT n = 51 Health Status: unhealthy Condition: gout Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 51 Sources: https://pubmed.ncbi.nlm.nih.gov/26989892 Page: p.2030
Skin rash	2% Disc. AE	800 mg 1 times / day multiple, oral Highest studied dose Dose: 800 mg, 1 times / day Route: oral Route: multiple Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/26989892 Page: p.2030	unhealthy, ADULT n = 51 Health Status: unhealthy Condition: gout Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 51 Sources: https://pubmed.ncbi.nlm.nih.gov/26989892 Page: p.2030

Sourcing

Vendor/Aggregator	ID	URL
Alfa Chemistry	26718-25-2	http://www.alfa-chemistry.com/search.aspx?q=26718-25-2
BOC Sciences	26718-25-2
ChemShuttle	139050	https://www.chemshuttle.com/catalogsearch/result/?q=139050
Compound Cloud	12082259
Compound Cloud	33584
Lan Pharmatech	LQT-B04043
Lan Pharmatech	LQT-B14870
MuseChem	I002754	https://www.musechem.com/product/I002754.html
Norris Pharm	NSZB-A235090
Norris Pharm	NSZB-A242660
Tetrahedron	TS69750	http://www.thsci.com/search.do?q=TS69750
eMolecules	50418047	https://orderbb.emolecules.com/search/#?query=50418047
mcule	MCULE-1116084857	https://mcule.com/MCULE-1116084857/

PubMed

Title	Date	PubMed
The Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout.	2017 Mar	27980008

Patents

Sample Use Guides

In Vivo Use Guide

In a clinical trial, patients with gout received 600 mg arhalofenate or 800 mg arhalofenate. In patients with type 2 diabetes mellitus, the dose was 200, 400 or 600 mg given once daily for 16 weeks.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 19:33:49 UTC 2023` Edited by `admin` on `Sat Dec 16 19:33:49 UTC 2023`
Record UNII	EWR4G9V8JG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Arhalofenic Acid

Common Name

English

MBX-102 acid

Common Name

English

(-)-Halofenic acid

Common Name

English

Benzeneacetic acid, 4-chloro-α-[3-(trifluoromethyl)phenoxy]-, (αR)-

Systematic Name

English

(2R)-2-(4-chlorophenyl)-2-[3-(trifluoromethyl)phenoxy]acetic acid

Systematic Name

English

(αR)-4-Chloro-α-[3-(trifluoromethyl)phenoxy]benzeneacetic acid

Systematic Name

English

Code System Code Type Description

CAS

23953-39-1

Created by admin on Sat Dec 16 19:33:50 UTC 2023 , Edited by admin on Sat Dec 16 19:33:50 UTC 2023

PRIMARY

PUBCHEM

12082255

Created by admin on Sat Dec 16 19:33:50 UTC 2023 , Edited by admin on Sat Dec 16 19:33:50 UTC 2023

PRIMARY

FDA UNII

EWR4G9V8JG

Created by admin on Sat Dec 16 19:33:50 UTC 2023 , Edited by admin on Sat Dec 16 19:33:50 UTC 2023

PRIMARY

EPA CompTox

DTXSID90477247

Created by admin on Sat Dec 16 19:33:50 UTC 2023 , Edited by admin on Sat Dec 16 19:33:50 UTC 2023

PRIMARY

Related Record Type Details


					V02QWF9PMI

METAGLIDASEN

RACEMATE -> ENANTIOMER

Amount:


					4HZ67LW8L7

OAT-4

TARGET -> INHIBITOR

Amount:


					X62226112J

INTERLEUKIN-1 .BETA. HUMAN

TARGET -> INHIBITOR

Amount:


					LGG1US7EOD

OATL-4

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					1P01UJR9X1

ARHALOFENATE

PRODRUG -> METABOLITE ACTIVE

Amount:

Related Record Type Details


					EWR4G9V8JG

Arhalofenic Acid

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: http://ard.bmj.com/content/71/Suppl_3/450.3 | https://www.ncbi.nlm.nih.gov/pubmed/19404482

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Cmax

AUC

T1/2

Doses

AEs

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: http://ard.bmj.com/content/71/Suppl_3/450.3 | https://www.ncbi.nlm.nih.gov/pubmed/19404482

C_max

T_1/2